« previous next »
Pages: [1]

Author Topic: European Commission grants marketing authorization for subcutaneous Tysabri  (Read 62 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9664
  • MS diagnosed 1980
  • Location: Pacific Northwest
European Commission grants marketing authorization for subcutaneous Tysabri
« on: April 07, 2021, 08:38:23 pm »
Tysabri may soon be available for subcutaneous administration, eliminating the need for trips to infusion centers, according to this article in StreetInsider (April 7, 2021):


https://bit.ly/3mthepc




Report to moderator   Logged
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9664
  • MS diagnosed 1980
  • Location: Pacific Northwest
FDA doesn't approve subcutaneous Tysabri
« Reply #1 on: May 06, 2021, 09:04:27 pm »
Well, maybe not.


This is from Biogen (April 28, 2021) and reports that the FDA has refused to approve its plan for subcutaneous administration of Tysabri:



https://bit.ly/3er1tNq
Report to moderator   Logged
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.
Pages: [1]
« previous next »
 

Related Topics

  Subject / Started by Replies Last post
1 Replies
170 Views 		Last post May 18, 2017, 03:36:23 pm
by agate
0 Replies
119 Views 		Last post January 26, 2018, 09:46:57 pm
by agate
0 Replies
59 Views 		Last post January 29, 2020, 09:35:32 pm
by agate
0 Replies
19 Views 		Last post April 18, 2021, 09:14:50 pm
by agate
0 Replies
21 Views 		Last post November 29, 2021, 09:01:35 pm
by agate